





UNIVERSITAT DE BARCELONA

B

Organ dysfunction in AHF PULMONARY EDEMA

Josep MASIP MD, PhD, FESC

Intensive Care Dept. Consorci Sanitari Integral Cardiology Dept. Hospital Sanitas CIMA. Barcelona Associate Professor Cardiology University of Barcelona. SPAIN

ACUTE NO CONFLICT OF INTEREST CARDIOVASCULAR CARE2015

LUNG DYSFUNCTION IN HEART FAILURE

Pulmonary Edema (Hydrostatic)

Starling forces imbalance in pulmonary capillaries

Alveolar fluid reabsorption (NO-dependent)

Alveolar fluid secretion (Cl⁻ / Na⁺ transport-driven)

Pulmonary capillary stress failure

Individual susceptibility and other forms of APE


Restrictive pattern

CHRONIC


Cardiac asthma


Pulmonary hypertension

ACUTE











Ware L. N Engl J Med 2005




Murral JF- Int J Tuberc Lung Dis 2011

NO dependence of alveolar fluid reabsorption




4-amino-5-methylamino-2-7-difluorofluorescein diacetate (DAF-FM DA)

B




Kaestle SM et al. Am J Physiol Lung Cell Mol Physiol 2007

Transcellular Na+ and CI- movement across alveolar epithelial cells




Londino et al. PNAS 2013

ALVEOLAR FLUID CLEARENCE




Verghese et al. J Appl Physiol 1999

ALVEOLAR FLUID CLEARENCE



Verghese et al. J Appl Physiol 1999

Plasma Epinephrine



Alveolar Fluid Clearance

Low reabsorption rate was not related to LVEF or PCWP

Table 6. *Comparison of outcomes in patients with intact vs. impaired alveolar fluid clearance*

	Alveolar Flu		
Outcome Variable	Impaired (n=16)	Intact (n=49)	<i>P</i> Value
Change in alveolar-arterial oxygen difference at 4 h Change in alveolar-arterial	4 ± 100	-40 ± 132	0.19
oxygen difference at 24 h Days of unassisted ventilation,	-167 ± 198	-268 ± 172	0.03
median (range) Hospital mortality, %	8 (0–27) 44%	23 (0–27) 26%	0.10 0.20

Values of change in alveolar-arterial oxygen difference at 4 and 24 h are means \pm SD.

Verghese et al. J Appl Physiol 1999

High altitude pulmonary edema (HAPE)

Genetic HAPE susceptibility

Defective NO synthesis


ET-1, oxidative stress, sympathetic outflow

Impaired pulmonary vasodilation

Augmented pulmonary vasoconstriction

Exaggerated hypoxic pulmonary hypertension

High altitude pulmonary edema (HAPE)



Duplain H, et al. N Engl J Med 2000


U. Scherrer et al. Prog Cardiovasc Dis 2010

To cause APE, the $\uparrow\uparrow\uparrow$ PAP has to be transmitted to the capillaries

Inhomogeneous hypoxic pulmonary vasoconstriction

Some capillaries are not protected Regional overperfusion with ↑ PCP

Hypoxia→ pulmonary veno-constriction Increased vascular resistance downstream to the site of fluid filtration Further increase in PCP




Impairment of alveolar fluid clearence

Capilary stress failure with altered permeability Scherrer U, et al. N Engl J Med 1996 U. Scherrer et al. Prog Cardiovasc Dis 2010

BAL: erythrocytes and large molecular weight proteins





Neurogenic pulmonary edema

Spinal cord injury, Severe epileptic grand mal seizure, Primary spinal cord hemorrhage, Intracerebral bleeding, Brain trauma, Subdural hematoma, Subarachnoid hemorrhage

Elevation of intracranial pressure

Rapid systemic sympathetic discharge

Peripheral vasoconstriction

Increase in systemic blood pressure

Elevated venous return Reduction LV compliance

Constriction of the pulmonary veins Hydrostatic increase in PCP


Damage to the alveolar wall and the leakage of fluid into the interstitium and intraalveolar space, hemorrhage and intra-alveolar accumulation of protein-rich edema fluid

APE in marathon runners




It is likely to occur as a result of overload of the vascular and lymphatic drainage systems because of the high cardiopulmonary demands of intense exercise, resulting in APE

SEVERE ACUTE CARDIOGENIC PULMONARY EDEMA




alveolar-capillary stress failure




The increase in capillary pressure or volume disrupts the anatomic configuration of the membrane

M. Guazzi et al. Chest 2003



Modified from M. Guazzi et al. Chest 2003



DM: Alveolar-capillary membrane gas conductance DLCO: Diffusion capacity Vc: Capillary Volume


M. Guazzi. J Cardiac Failure 2008

Pulmonary function in <u>CHRONIC HF</u> patients according to Peak-VO2

Peak VO_2	n	FVC	FEV-1	DLCO	DM	VC
<12	25	67%	76%	65	27.7	83
12-16	75	80%*	85%*	80*	30.3	104
16-20	64	85%*	90%*	80*	31.1	103*
>20	26	87%*	98%*	90*	42.3*	111*

* p> 0.05 or 0.01


P. Agostoni. Pulmonary Pharmacology & Therapeutics 2007




Expert Rev. Respir. Med. © Future Science Group (2012)

Tanabe T Expert Rev Resp Med 2012

Prevalence asthma syndromes in > 65 years is 6-10% Elderly with CHF have 35% cardiac asthma (3.5 times greater)



Tanabe T Expert Rev Resp Med 2012



Denzil L. Moraes. Circulation. 2000

Conclusions

• Hydrostatic pulmonary edema is the common clinical presentation of LV-AHF. An imbalance in the starling forces in the capillaries is the main pathophysiological mechanism, but NO-dependent alveolar fluid reabsorption, Cl⁻ and Na⁺ transport alveolar fluid secretion and alveolar-capillary stress failure with inflammatory activation are other important contributing factors

• Individual susceptibility may explain why in different scenarios some patients tend to present severe APE

• Chronic and severe decompensations may lead to persisting alterations in the lung parenchyma and bronchi with a restrictive pattern, cardiac asthma and finally, pulmonary hypertension